Sign In
- Home
- Share Prices
- AQSE Share Prices
- Euronext
- US Share Prices
- Stock Tips
- Share Chat
- FX
- News & RNS
- Media
- Trading Brokers
- Finance Tools
- Members
Latest Share Chat
CSP.L Share News (CSP)
CSP Share
Price
CSP Share
News
CSP Share
Chat
CSP Share
Trades
CSP
Live RNS
CSP Share
Charts
CSP Broker
Ratings
CSP Directors
Deals
CSP Financial
Diary
CSP
Fundamentals
CSP Short
Positions
CSP
Media
CSP Company
Research
CSP Company
Timeline
- There is currently no data for CSP
Wednesday broker round-up
Barclays: Berenberg reiterates buy with a target price of 220p.
Aston Martin: Citigroup reiterates buy with a target price of 2,800p.
Segro: JP Morgan reiterates neutral with a target price of 1,195p.
Sainsbury: Barclays reiterates overweight with a target price of 305p.
GlaxoSmithKline: Liberum reiterates buy with a target price of 1,700p.
On The Beach: Liberum reiterates hold with a target price of 380p.
888 Holdings: Peel Hunt reiterates buy with a target price of 500p.
Countryside Properties: Peel Hunt reiterates buy with a target price of 560p.
Redrow: Numis reiterates buy with a target price of 715p.
Accesso: Numis upgrades to buy with a target price of 800p.
International Airlines Group: Credit Suisse reiterates outperform with a target price of 256p.
Centrica: Credit Suisse reiterates outperform with a target price of 70p.
Latest CSP News
- Inmarsat set for FTSE demotion in quarterly review
31 May 2016 - Thursday broker round-up
19 May 2016 - Countryside Properties Profit, Revenue Up In First Half
18 May 2016 - Earnings, Trading Statements Calendar - Week Ahead
11 May 2016 - Countryside On Track As Sales Rise And Selling Price Surges
13 Apr 2016 - Broker tips: TUI, Countryside Properties, Hammerson
31 Mar 2016 - Peel Hunt starts Countryside Properties at 'buy'
31 Mar 2016 - JP Morgan Cazenove starts Countryside Properties at 'overweight'
24 Mar 2016
Related News
GSK, Hansoh's targeted cancer drug hits main survival goal in China trial
* GSK partner Hansoh reports first late-stage data for experimental lung cancer drug
GSK says Ris-Rez meets primary endpoint in phase 3 lung cancer trial
(Alliance News) - GSK PLC on Friday announced that risvutatug rezetecan has delivered "meaningful" survival data in a "pivotal" trial for advanced or ...
GSK hails 'milestone' drug trial results in China
(Sharecast News) - A targeted lung cancer treatment developed by GSK has shown promising results in the latest trials in China, the pharma blue chip c...
CSP.L News
Inmarsat set for FTSE demotion in quarterly review
(ShareCast News) - Satellite communications company Inmarsat could be pushed out of the FTSE 100 by Hikma Pharmaceuticals in June, according to the FT...
Thursday broker round-up
(ShareCast News) - Countryside Properties: JP Morgan reiterates overweight with a 280p target. SSP Group: Citigroup retains buy with a 340p target. P...
Broker tips: TUI, Countryside Properties, Hammerson
(ShareCast News) - TUI AG's 'buy' rating and target price of €22.60 (£17.85) were left unchanged by Nomura after the company said summer holidays were...
Peel Hunt starts Countryside Properties at 'buy'
(ShareCast News) - Peel Hunt initiated coverage of Countryside Properties at 'buy' with a 290p price target. It said Countryside provides investors wi...
JP Morgan Cazenove starts Countryside Properties at 'overweight'
(ShareCast News) - JP Morgan Cazenove initiated coverage of Countryside Properties at 'overweight' with a 280p price target. It said the company was d...
Follow the stocks
